Silence Therapeutics PLC
Company Profile
Business description
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Contact
12 Hammersmith Grove
LondonW6 7AP
GBRT: +44 2034576900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
88
Stocks News & Analysis
stocks
Is SpaceX a threat to this ASX giant?
stocks
Chart of the Week: This ASX top pick might be overlooked
stocks
ASX share undervalued as margins expected to rebound
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,050.20 | 23.00 | -0.25% |
| CAC 40 | 8,467.98 | 37.19 | 0.44% |
| DAX 40 | 25,026.80 | 92.13 | 0.37% |
| Dow JONES (US) | 51,564.70 | 72.15 | 0.14% |
| FTSE 100 | 10,399.70 | 108.91 | -1.04% |
| HKSE | 23,924.81 | 387.35 | -1.59% |
| NASDAQ | 26,517.93 | 496.28 | 1.91% |
| Nikkei 225 | 71,644.53 | 591.04 | 0.83% |
| NZX 50 Index | 13,415.34 | 52.03 | 0.39% |
| S&P 500 | 7,500.58 | 80.48 | 1.08% |
| S&P/ASX 200 | 8,831.30 | 25.30 | -0.29% |
| SSE Composite Index | 4,090.48 | 17.59 | -0.43% |